Japanese drugmaker Chugai now has two positive phase 3 studies backing the efficacy and safety of the antibody satralizumab to treat neuromyelitis optica spectrum disorder (NMOSD). Great news for the patient community of…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
